Bio-Rad Labs Inc. A Stock
Bio-Rad Labs Inc. A Stock
The price for the Bio-Rad Labs Inc. A stock decreased slightly today. Compared to yesterday there is a change of -€1.400 (-0.480%).
Currently there is a rather positive sentiment for Bio-Rad Labs Inc. A with 3 Buy predictions and 0 Sell predictions.
As a result the target price of 298 € shows a slightly positive potential of 4.27% compared to the current price of 285.8 € for Bio-Rad Labs Inc. A.
For the coming years our community has positive and negative things to say abot the Bio-Rad Labs Inc. A stock. Criterium "Revenue growth" gathered the most positive votes but regarding "Revenue growth" there were negative voices in the community.
Pros and Cons of Bio-Rad Labs Inc. A in the next few years
Pros
?
W********* I********* f** t** n*** y****
?
M***** P*******
?
S********** s********
Cons
?
B****
?
G***** c******* t* c**********
?
C******** o* t** e**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Bio-Rad Labs Inc. A vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Bio-Rad Labs Inc. A | -0.480% | 2.732% | 11.380% | 30.502% | 10.818% | -24.392% | -54.272% |
| CONMED Corp. | 0.500% | 7.979% | 42.958% | -6.881% | 16.000% | -62.056% | -64.696% |
| Penumbra Inc | 0.290% | -0.786% | 0.507% | 26.239% | 4.204% | 1.314% | 23.268% |
| Glaukos Corp | 10.770% | 8.271% | 18.033% | 73.494% | 49.223% | 110.219% | 239.623% |
Comments
Bio-Rad Laboratories (BIO) had its "outperform" rating reaffirmed by Royal Bank Of Canada. They now have a $320.00 price target on the stock.
Show more
Ratings data for BIO provided by MarketBeat
Bio-Rad Laboratories (NYSE:BIO) had its price target raised by analysts at Citigroup Inc. from $350.00 to $375.00. They now have a "buy" rating on the stock.
Show more
Ratings data for BIO provided by MarketBeat
Bio-Rad Laboratories, Inc. (NYSE: BIO) had its price target raised by analysts at Royal Bank Of Canada from $387.00 to $409.00. They now have an "outperform" rating on the stock.
Show more
Ratings data for BIO provided by MarketBeat